APA

Vesole D. H., Bilotti E., Richter J. R., McNeill A., McBride L., Raucci L., Anand P., Bednarz U., Ivanovski K., Smith J., Batra V., Aleman A., Sims T., Guerrero L., Mato A. & Siegel D. S. (20151204). Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. : British journal of haematology.

Chicago

Vesole David H, Bilotti Elizabeth, Richter Joshua R, McNeill Ann, McBride Laura, Raucci Laura, Anand Palka, Bednarz Urszula, Ivanovski Kristin, Smith Judith, Batra Veena, Aleman Adolfo, Sims Taliah, Guerrero Laura, Mato Anthony and Siegel David S. 20151204. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. : British journal of haematology.

Harvard

Vesole D. H., Bilotti E., Richter J. R., McNeill A., McBride L., Raucci L., Anand P., Bednarz U., Ivanovski K., Smith J., Batra V., Aleman A., Sims T., Guerrero L., Mato A. and Siegel D. S. (20151204). Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. : British journal of haematology.

MLA

Vesole David H, Bilotti Elizabeth, Richter Joshua R, McNeill Ann, McBride Laura, Raucci Laura, Anand Palka, Bednarz Urszula, Ivanovski Kristin, Smith Judith, Batra Veena, Aleman Adolfo, Sims Taliah, Guerrero Laura, Mato Anthony and Siegel David S. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. : British journal of haematology. 20151204.